Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity

Fig. 6

Proposed mechanism of action of DSP107 for activation of innate and adaptive anticancer immunity. The tumor microenvironment suppresses infiltrating immune cells, including macrophages and T cells I) DSP107 binds to CD47 overexpressed on cancer cells and abrogates the CD47-SIRPα interaction II) Consequently, macrophage-mediated phagocytosis of cancer cells is restored III) Upon phagocytic uptake, tumor antigens are presented to T cells in MHC, thereby triggering activation of tumor-reactive T cells IV) Upon recognition of cancer cells, 4-1BB is upregulated on T cells, whereupon DSP107 provides costimulatory signaling that augments antitumor T cell immunity. T cell-mediated lysis of cancer cells then further leads to phagocytic uptake of apoptotic cancer cells to continue driving the innate/adaptive anticancer immunity cycle. The figure was created with BioRender.com

Back to article page